In-stent restenosis (ISR) is one of the main complications in patients undergoing percutaneous coronary angioplasty, and microRNAs participate in the contractile-to-synthetic phenotypic switch of vascular smooth muscle cells, a hallmark of restenosis development. MicroRNAs (miRNAs) can be released into circulation from injured tissues, enticing a potential role as noninvasive biomarkers. We aimed to evaluate circulating levels of miRNA-23b, miRNA-143, and miRNA-145 as diagnostic markers of ISR. 142 patients with coronary artery disease undergoing successful angioplasty and a follow-up angiography were included. Subjects were classified according to the degree of obstruction at the angioplasty site into cases (≥50%) or controls (<50%). Total RNA was isolated from plasma to quantify circulating miRNAs levels, and the ROC curves were constructed. Among circulating miRNAs assessed, miRNA-23b and miRNA-143 were significantly lower in cases (miRNA-23b: 18.4x10^{-5} and miRNA-143: 13.7x10^{-5}) than controls (miRNA-23b: 5.2x10^{-5}, p < 0.0001; miRNA-143: 4.0x10^{-5}, p < 0.0001). Plasma levels of miRNA-145 showed no significant differences. The analysis of the ROC curves showed an area under the curve for miRNA-23b of 0.71 (95% CI: 0.62-0.80, p < 0.0001) and 0.69 for miRNA-143 (95% CI: 0.60-0.78, p < 0.0001). Our data suggest that plasma levels of miRNA-23b and miRNA-143 could be useful as noninvasive biomarkers of ISR.

1. Introduction

Restenosis results from a reduced diameter of the lumen of a blood vessel following percutaneous coronary angioplasty (PCA). Angiographically, restenosis is defined dichotomously as a luminal narrowing of more than 50% in the follow-up angiography, which occurs as a consequence of arterial damage with subsequent neointimal tissue proliferation [1]. Although a reduction in the percentage of subjects developing restenosis has been observed at the same time PCA has evolved, in-stent restenosis (ISR) continues to be one of the main complications in patients undergoing this procedure [2]. Moreover, the uptake of percutaneous intervention in larger numbers of patients with increasingly complex lesion characteristics and disease comorbidities means that the number of patients presenting with restenosis remains considerable in absolute terms [3]. Several pathogenic mechanisms have been associated with restenosis development, among which we can find elastic recoil of the vessels, arterial remodelling, and neointimal hyperplasia. The two latter particularly related to ISR though a phenotypic change of the vascular smooth muscle cells (VSMCs)
from a contractile to a proliferative state under the induction of platelet-derived growth factor (PDGF), resulting in accumulation of VSMC in the intimal arterial layer [4–6].

MicroRNAs (miRNAs) are short noncoding RNA molecules that negatively affect gene expression through mRNA cleavage or inhibition of protein translation, resulting in profound and complex regulatory networks [7]. In the cardiovascular system, miRNAs regulate basic functions in almost all cell types including cardiac muscle, endothelial cells, smooth muscle, inflammatory cells, and fibroblasts and, therefore, play a pivotal role in the pathogenesis of several cardiovascular diseases (CVDs). Numerous miRNAs have been implicated in the contractile-to-synthetic phenotypic switch of VSMC, including miRNA-143/145, miRNA-23b, miRNA-22, miRNA-133, miRNA-125a, miRNA-195, miRNA-663, miRNA-21, miRNA-221/222, miRNA-146a, miRNA-206, miRNA-181b, and miRNA-31, among others [8]. For instance, the miRNA-143/145 cluster coordinates the phenotypic modulation of VSMC through a cooperative network of transcription factors, such as Kruppel-Like Factor 5 (KLF5), Kruppel-Like Factor 4 (KLF4), and the potent transcriptional coactivator myocardin (MYOCID), to promote differentiation and suppress VSMCs proliferation [9, 10]. Thereby, deficiency of miRNA-145/143 promotes the synthetic phenotype of VSMCs. Furthermore, adenosinemediated gene transfer of miRNA-145/143, which downregulate the expression of this miRNAs after injury, inhibits neointimal lesion formation in injured rat carotid arteries [11]. On the other hand, miRNA-23b plays a critical role in angiogenesis, cardiac ischemia, and homeostasis of endothelial cells [12]. Moreover, the overexpression of miRNA-23b in balloon-injured arteries by Ad-miRNA-23b markedly decreased neointimal hyperplasia in VSMC, in vitro [13]. Yet, another relevant and highly attractive feature of miRNAs corresponds to their remarkable extracellular stability, an outcome that has received especial attention due to a promising role as blood-based biomarkers for diagnosis and prognosis of several illnesses [14]. Considering this background, we evaluated levels of circulating miRNA-23b, miRNA-143, and miRNA-145 as potential diagnostic markers of ISR in Chilean subjects with coronary artery disease (CAD).

2. Methods

2.1. Subjects. A diagnostic test study was designed using unpaired incident cases and controls, including 142 patients with CAD who underwent successful coronary artery angioplasty and follow-up coronary angiography after at least 6 months of stent implantation. Participants were classified in two groups: (1) case group, with stenosis ≥ 50% and (2) control group, with stenosis < 50%, a criterion concordant with the degree of obstruction at the angioplasty site. The obstruction was measured in the follow-up and was regarded as the gold standard. Demographic, anthropometric, and cardiovascular risk factors such as diabetes, hypertension, and dyslipidemia were recorded. Patients were invited to participate in the cardiology services of public Chilean hospitals, Dr. Hernán Henríquez Aravena Hospital (Temuco, Chile) and Dr. Guillermo Grant Benavente (Concepción, Chile). All subjects enrolled were included in this study after accepting their participation by signing a written informed consent approved by both, the Ethics Committees of University of La Frontera and Health Service of Concepción.

2.2. Sampling and RNA Extraction. For detection of circulating miRNAs, we obtained a sample of whole blood anticoagulated with EDTA at the time of the angiographic control using standard venipuncture blood extraction. Then, plasma was separated by centrifugation (15 minutes at 3.000 rpm) and transferred into nuclease-free tubes for subsequent storage at -80°C until RNA extraction procedures. Plasma RNA was isolated using the miRNeasy Mini Kit (Qiagen) following the supplemental protocol for RNA purification, including miRNAs. Prior to extraction, 5 μL of the exogenous miRNA-39 (5 nM) of Caenorhabditis elegans (cel-miRNA-39) was added to 0.2 mL of plasma, for the normalization of technical variations (sample quality and extraction efficiency) between samples.

2.3. Circulating miRNAs. To quantify circulating miRNA-143, miRNA-145, and miRNA-23b levels from total RNA, a first strand of complementary DNA (cDNA) was synthesized using the TaqMan® Advanced miRNA (Applied Biosystems) synthesis kit, which polyadenylated the 3′ end and added an adaptor to the 5′ end of all miRNA sequences contained in the sample. Then, miRNA detection was completed by quantitative polymerase chain reaction (qPCR), using the TaqMan® Advanced miRNA Assays for each selected miRNA (Thermo Fisher Scientific assay IDs 478713_mir, 477915_mir and 477991_mir). These assays were performed in a StepOne™ Real-Time PCR System (Applied Biosystems) using the following thermocycling protocol: 20 seconds at 95°C and 40 cycles of 95°C for 1 second and 60°C for 20 seconds. All qPCR assays were performed in duplicate, and miRNAs quantification was obtained by the 2–ΔΔCt method, using cel-miRNA-39 to normalize miRNA expression.

2.4. Statistical Analysis. The statistical analysis was carried out with the software SPSS 25.0 (SPSS, Inc., Chicago, USA). The unpaired two-tailed t-test or its nonparametric equivalent (Mann–Whitney U test) was used to assess differences between demographic and biometric characteristics and circulating miRNA quantification between cases and controls. The comparisons between dichotomous variables were analyzed using the chi-squared test. The receiver operating characteristic (ROC) curves were generated to evaluate the diagnostic capacity of each circulating miRNA, using the area under the curve (AUC) to determine cutoff values that maximize sensitivity and specificity. A value of p < 0.05 was defined as statistically significant.

3. Results

3.1. Clinical Characteristics of Subjects. Clinical and anthropometric characteristics of the participants are shown in Table 1. No significant differences were observed between
Table 1: Clinical and anthropometric characteristics of cases and controls.

| Parameter              | Controls (n = 61) | Cases (n = 81) | p value |
|------------------------|------------------|----------------|---------|
| Age (years)            | 67.0 ± 9.3       | 64.1 ± 10.3    | 0.640   |
| BMI (kg/m²)            | 27.6 ± 4.2       | 28.2 ± 3.9     | 0.326   |
| SBP (mmHg)             | 130.7 ± 25.9     | 130.4 ± 23.6   | 0.942   |
| DBP (mmHg)             | 69.5 ± 12.2      | 73.1 ± 12.1    | 0.081   |
| HR (bpm)               | 68.6 ± 11.0      | 71.0 ± 12.2    | 0.301   |
| Male (%)               | 66.7             | 80.5           | 0.042   |
| BMS (%)                | 65.8             | 86.4           | 0.002   |
| Diabetes mellitus (%)  | 28.0             | 41.0           | 0.091   |
| Dyslipidemia (%)       | 69.3             | 74.4           | 0.489   |
| Hypertension (%)       | 84.2             | 85.9           | 0.769   |
| Obesity (%)            | 26.3             | 27.4           | 0.870   |
| Lesion vessel (%)      |                  |                |         |
| LMCA                   | 1.1              | 1.1            | —       |
| LAD                    | 47.5             | 44.8           | —       |
| CX                     | 18.3             | 31.7           | —       |
| RCA                    | 33.1             | 22.4           | —       |
| Diameter (mm)          | 3.1 ± 0.3        | 2.9 ± 0.1      | 0.673   |
| Length (mm)            | 22.3 ± 4.1       | 22.6 ± 3.4     | 0.710   |

Values expressed as mean ± standard deviation. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; ISR: in-stent restenosis; BMS: bare-metal stent; LMCA: left main coronary artery; LAD: left anterior descending artery; CX: circumflex artery; RCA: right coronary artery.

In the present study, we evaluated circulating levels of miRNA-23b, miRNA-143, and miRNA-145 in patients undergoing successful coronary arterial angioplasty, with a follow-up coronary angiography after at least 6 months since stent implantation, in order to identify differences in miRNA levels between patients who developed ISR versus controls.

ISR is one of the most relevant complications after stent placement and is characterized by the phenotypic switch of VSMC. Different reports indicate that miRNAs play a significant role in this process, for instance, miRNA-143, miRNA-145, and miRNA-23b maintain a contractile phenotype in VSMCs of healthy blood vessels [9, 10, 15–19]; therefore, circulating miRNAs could reflect cellular processes occurring in the blood vessels after stent implantation [16, 20]. Moreover, due to miRNAs can be found in several body fluids, their potentials to identify different pathologies have been widely explored in CVD such as acute myocardial infarction [21], CAD [22], and stroke [23]. In the case of ISR, we here show that miRNA-23b could be used as a noninvasive biomarker to identify patients with ISR. This miRNA is highly expressed in cell cultures of VSMC, decreasing their proliferation, differentiation, and migration [13]. In addition, in vitro studies show that miRNA-23b regulates the expression of the Fork-head Box protein (Fox04) [24], which represses differentiation of smooth muscle cells and activates the migration of VSMC in response to TNF-α and urokinase-type plasminogen activator (uPA) [15, 19] through the MEK/ERK signaling pathway [25] and SMAD3 [19], a protein important for the proliferation of VSMC [26]. These data could explain the decreased levels of miRNA-23b detected in the plasma of patients with ISR.

Similarly, studies have reported AUC values of 0.839 for miRNA-143 and 0.871 for miRNA-145, in addition to high specificity and sensitivity (0.9 and 0.7), respectively [27]. We also observed a repression of miRNA-143 in subjects who develop ISR. Apparently, the most important trigger of miRNA-143 repression is PDGF, a key element in the mediation of vascular response to injury acting through the proto-oncogene tyrosine-protein kinase SRC and phosphoprotein p53, with the net result of promoting both proliferation and migration of VSMC [16]. A significant difference in plasma levels of miRNA-143 in restenosis of vascular occlusive disease of the lower extremities has also been reported, with significantly decreased expression [28].

The availability of noninvasive biomarkers with high resolution for specific biological processes could add significant incremental value to the clinical arsenal currently available for short-term follow-up of patients treated with PCA, which could reduce the number of candidates for invasive angiographic control [29]. Identification of differential miRNAs and their potential use as biomarkers in patients with ISR still requires greater consistency. Moreover, miRNAs are extremely stable in plasma/serum and resistant to some hard conditions including low and high pH, boiling, and long storage and can withstand repetitive freezing and thawing cycles [30]. We also highlight the need for longitudinal studies depicting changes in miRNA levels from the first...
stages of the intervention. Currently, incipient efforts have
been reported to a promissory use of miRNAs for stent
intervention in animal models, which holds potential for
personalized therapy [31, 32].

In conclusion, our data show decreased levels of miRNA-
23b and miRNA-143 in the plasma of subjects with ISR
versus controls, a differential result that could confer these
miRNAs a potential use as noninvasive biomarkers for ISR.

---

**Table 2:** Diagnostic characteristics for plasma miRNA-23b and
miRNA-143.

| miRNAs      | Sensitivity | Specificity | PPV  | NPV  |
|-------------|-------------|-------------|------|------|
| miRNA-23b   | 0.59        | 0.84        | 0.83 | 0.61 |
| miRNA-143   | 0.56        | 0.82        | 0.80 | 0.58 |
| miRNA-23b/miRNA-143 | 0.82 | 0.68 | 0.77 | 0.73 |

PPV: positive predictive value; NPV: negative predictive value.
Data Availability
The data and materials in the current study are available from the corresponding author on reasonable request.

Conflicts of Interest
The authors declare no conflict of interest.

Authors’ Contributions
The study design, writing the review, and editing were contributed by N.S., K.S., T.Z., F.L., and L.S.; the laboratory analysis was done by G.R., J.H., C.R., and J.R.; the clinical analysis was done by B.B., L.P., and F.L.; the data analysis was done by N.S., L.B., F.L., and L.S.

Acknowledgments
This research was funded by FONDECYT-Chile (Grant numbers DI15-0033 and DI19-2018).

References
[1] G. D. Dangas, B. E. Claessen, A. Caixeta, E. A. Sanidas, G. S. Mintz, and R. Mehran, “In-Stent restenosis in the drug-eluting stent era,” Journal of the American College of Cardiology, vol. 56, no. 23, pp. 1897–1907, 2010.
[2] F. Du and J. Zhou, “Vascular intervention: from angioplasty to bioresorbable vascular scaffold,” Advances in Experimental Medicine and Biology, vol. 1097, pp. 181–189, 2018.
[3] S. Cassese, R. A. Byrne, T. Tada et al., “Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography,” Heart, vol. 100, no. 2, pp. 153–159, 2013.
[4] D. Buccheri, D. Piraino, G. Andolina, and B. Cortese, “Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment,” Journal of Thoracic Disease, vol. 8, no. 10, pp. E1150–E1162, 2016.
[5] S. O. Marx, H. Totary-Jain, and A. R. Marks, “Vascular smooth muscle cell proliferation in restenosis,” Circulation. Cardiovascular Interventions, vol. 4, no. 1, pp. 104–111, 2011.
[6] D. Gomez and G. K. Owens, “Smooth muscle cell phenotypic switching in atherosclerosis,” Cardiovascular Research, vol. 95, no. 2, pp. 156–164, 2012.
[7] C. Catalanotto, C. Cocioni, and G. Zardo, “MicroRNA in control of gene expression: an overview of nuclear functions,” International Journal of Molecular Sciences, vol. 17, no. 10, p. 1712, 2016.
[8] C. Indolfi, C. Iaconetti, C. Gareri, A. Polimeni, and S. De Rosa, “Non-coding RNAs in vascular remodeling and restenosis,” Vascular Pharmacology, vol. 114, pp. 49–63, 2019.
[9] K. R. Cordes, N. T. Sheehy, M. P. White et al., “MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity,” Nature, vol. 460, no. 7256, pp. 705–710, 2009.
[10] Y. Cheng, X. Liu, J. Yang et al., “MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation,” Circulation Research, vol. 105, no. 2, pp. 158–166, 2009.
[11] D. Wang and A. G. Atanasov, “The microRNAs regulating vascular smooth muscle cell proliferation: a minireview,” International Journal of Molecular Sciences, vol. 20, no. 2, p. 324, 2019.
[12] C. Bang, J. Fiedler, and T. Thum, “Cardiovascular importance of the microRNA-23/27/24 family,” Microcirculation, vol. 19, no. 3, pp. 208–214, 2012.
[13] M. Chen, J. Shi, W. Zhang et al., “MiR-23b controls TGF-β1 induced airway smooth muscle cell proliferation via direct targeting of Smad3,” Pulmonary Pharmacology & Therapeutics, vol. 42, pp. 33–42, 2017.
[14] V. Ghai and K. Wang, “Recent progress toward the use of circulating microRNAs as clinical biomarkers,” Archives of Toxicology, vol. 90, no. 12, pp. 2959–2978, 2016.
[15] R. Hutcheson, R. Terry, J. Chaplin et al., “MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 4, pp. 727–736, 2013.
[16] M. Quintavalle, L. Elia, G. Condorelli, and S. A. Courtneidge, “MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro,” The Journal of Cell Biology, vol. 189, no. 1, pp. 13–22, 2010.
[17] M. He, Y. Gong, J. Shi et al., “Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis,” PLoS One, vol. 9, no. 11, article e112043, 2014.
[18] D. Santovito, C. Mandolini, P. Marcantonio et al., “Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients,” Expert Opinion on Therapeutic Targets, vol. 17, no. 3, pp. 217–223, 2013.
[19] C. Iaconetti, S. de Rosa, A. Polimeni et al., “Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro,” Cardiovascular Research, vol. 107, no. 4, pp. 522–533, 2015.
[20] C. Gareri, S. De Rosa, and C. Indolfi, “MicroRNAs for restenosis and thrombosis after vascular injury,” Circulation Research, vol. 118, no. 7, pp. 1170–1184, 2016.
[21] C. Cheng, Q. Wang, W. You, M. Chen, and J. Xia, “MiRNAs as biomarkers of myocardial infarction: a meta-analysis,” PLoS One, vol. 9, no. 2, article e88566, 2014.
[22] C. Schulte, S. Molz, S. Appelbaum et al., “miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease,” PLoS One, vol. 10, no. 12, article e0145930, 2015.
[23] M. Li and J. Zhang, “Circulating MicroRNAs: potential and emerging biomarkers for diagnosis of cardiovascular and cerebrovascular diseases,” BioMed Research International, vol. 2015, Article ID 730535, 9 pages, 2015.
[24] W. Wang, Y. Wang, W. Liu, and A. J. van Wijnen, “Regulation and biological roles of the multifaceted miRNA-23b (MIR23B),” Gene, vol. 642, pp. 103–109, 2018.
[25] R. J. Wang, Y. H. Zheng, P. Wang, and J. Z. Zhang, “Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 1, pp. 765–771, 2015.
[26] T. Luo, S. Cui, C. Bian, and X. Yu, “Crosstalk between TGF-β1/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis,” Molecular and Cellular Biochemistry, vol. 389, no. 1-2, pp. 169–176, 2014.
[27] H. Meijiao, S. Jing, L. Yue, L. Weimin, and G. Yongtai, “Plasma microRNA-143 and microRNA-145 as a potential noninvasive biomarker for In-stent restenosis,” *Heart*, vol. 97, Supplement 3, pp. A155–A156, 2011.

[28] Z. H. Yu, H. T. Wang, and C. Tu, “Diagnostic value of microRNA-143 in predicting in-stent restenosis for patients with lower extremity arterial occlusive disease,” *European Journal of Medical Research*, vol. 22, no. 1, p. 2, 2017.

[29] C. Tana, M. A. Giamberardino, and F. Cipollone, “MicroRNA profiling in atherosclerosis, diabetes, and migraine,” *Annals of Medicine*, vol. 49, no. 2, pp. 93–105, 2017.

[30] K. Felekkis and C. Papanephytou, “Challenges in using circulating micro-RNAs as biomarkers for cardiovascular diseases,” *International Journal of Molecular Sciences*, vol. 21, no. 2, p. 561, 2020.

[31] G. Santulli, A. Wronska, K. Uryu et al., “A selective microRNA-based strategy inhibits restenosis while preserving endothelial function,” *The Journal of Clinical Investigation*, vol. 124, no. 9, pp. 4102–4114, 2014.

[32] D. Wang, T. Deuse, M. Stubendorff et al., “Local MicroRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 35, no. 9, pp. 1945–1953, 2015.